Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) — Tangible Net Worth Ratio
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has a Tangible Net Worth Ratio of 97.1% as of December 2025. This metric is calculated by deducting intangible assets (CN¥60.87 Million) from net assets (CN¥2.12 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 688505 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Tangible Net Worth Ratio (2005–2025)
This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 21 annual periods from 2005 to 2025. As of December 2025, the ratio stands at 97.1%, reflecting net assets of CN¥2.12 Billion with intangible assets of CN¥60.87 Million CNY. See 688505 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025, covering 21 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see how much is Shanghai Fudan-Zhangjiang Bio-Pharmaceut worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 97.1% | CN¥2.12 Billion | CN¥60.87 Million | CN¥2.39 Billion | ▲ +0.1 pp |
| 2024 | 97.0% | CN¥2.31 Billion | CN¥68.65 Million | CN¥2.59 Billion | ▲ +0.7 pp |
| 2023 | 96.3% | CN¥2.36 Billion | CN¥86.35 Million | CN¥2.88 Billion | ▲ +0.7 pp |
| 2022 | 95.7% | CN¥2.25 Billion | CN¥97.15 Million | CN¥2.98 Billion | ▲ +1.0 pp |
| 2021 | 94.7% | CN¥2.19 Billion | CN¥116.47 Million | CN¥2.78 Billion | ▼ -1.0 pp |
| 2020 | 95.7% | CN¥2.01 Billion | CN¥86.85 Million | CN¥2.50 Billion | ▲ +3.8 pp |
| 2019 | 91.9% | CN¥933.15 Million | CN¥75.43 Million | CN¥1.56 Billion | ▼ -6.9 pp |
| 2018 | 98.8% | CN¥993.28 Million | CN¥11.99 Million | CN¥1.46 Billion | ▲ +0.4 pp |
| 2017 | 98.4% | CN¥892.48 Million | CN¥13.93 Million | CN¥1.15 Billion | ▼ -0.4 pp |
| 2016 | 98.9% | CN¥873.05 Million | CN¥9.74 Million | CN¥1.12 Billion | ▲ +0.2 pp |
| 2015 | 98.6% | CN¥765.84 Million | CN¥10.37 Million | CN¥1.02 Billion | ▼ -0.9 pp |
| 2014 | 99.6% | CN¥676.42 Million | CN¥2.87 Million | CN¥824.48 Million | ▼ -0.1 pp |
| 2013 | 99.6% | CN¥565.92 Million | CN¥2.10 Million | CN¥749.22 Million | ▲ +0.3 pp |
| 2012 | 99.4% | CN¥260.11 Million | CN¥1.65 Million | CN¥537.30 Million | ▼ -0.6 pp |
| 2011 | 100.0% | CN¥201.07 Million | CN¥77.00K | CN¥358.88 Million | ▲ +0.0 pp |
| 2010 | 99.9% | CN¥168.71 Million | CN¥95.00K | CN¥304.15 Million | ▲ +0.0 pp |
| 2009 | 99.9% | CN¥168.37 Million | CN¥110.00K | CN¥298.83 Million | ▲ +0.3 pp |
| 2008 | 99.7% | CN¥75.88 Million | CN¥246.00K | CN¥158.45 Million | ▲ +1.1 pp |
| 2007 | 98.6% | CN¥71.04 Million | CN¥1.01 Million | CN¥130.38 Million | ▲ +6.5 pp |
| 2006 | 92.0% | CN¥101.70 Million | CN¥8.10 Million | CN¥145.02 Million | ▼ -5.0 pp |
| 2005 | 97.0% | CN¥123.73 Million | CN¥3.69 Million | CN¥142.91 Million | — |